BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ixazomib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ixazomib\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04009109-2848@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ixazomib: Phase 2 readout est. (NCT04009109)
DESCRIPTION:Ixazomib\, phase 2.\nStudy: Study of Lenalidomide/Ixazomib/Dexa
 methasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnos
 ed MM\nEstimated primary completion: December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ixazomib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04009109
URL:https://assetmemo.bio/drug/ixazomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04068597-2848@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Ixazomib: Phase 1/2 readout est. (NCT04068597)
DESCRIPTION:Ixazomib\, phase 1/2\, Multiple Myeloma.\nStudy: Study to Evalu
 ate CCS1477 (Inobrodib) in Haematological Malignancies\nEstimated primary 
 completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ixazomib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04068597
URL:https://assetmemo.bio/drug/ixazomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02343042-2848@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ixazomib: Phase 1/2 readout est. (NCT02343042)
DESCRIPTION:Ixazomib\, phase 1/2\, Multiple Myeloma.\nStudy: Selinexor and 
 Backbone Treatments of Multiple Myeloma Patients\nEstimated primary comple
 tion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ixa
 zomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT02343042
URL:https://assetmemo.bio/drug/ixazomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03783416-2848@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Ixazomib: Phase 1 readout est. (NCT03783416)
DESCRIPTION:Ixazomib\, phase 1.\nStudy: SIZOMUS Safety of Ixazomib Targetin
 g Plasma Cells in Multiple Sclerosis\nEstimated primary completion: 31 Jul
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/ixazomib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03783416
URL:https://assetmemo.bio/drug/ixazomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03618537-2848@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Ixazomib: Phase 2 readout est. (NCT03618537)
DESCRIPTION:Ixazomib\, phase 2.\nStudy: Ixazomib Maintenance Study in Patie
 nts With AL Amyloidosis\nEstimated primary completion: August 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/ixazomib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT03618537
URL:https://assetmemo.bio/drug/ixazomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04790474-2848@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Ixazomib: Phase 2 readout est. (NCT04790474)
DESCRIPTION:Ixazomib\, phase 2\, Multiple Myeloma.\nStudy: Ixazomib-pomalid
 omide-dexamethasone as Second or Third-line Combination Treatment for Pati
 ents With Relapsed and Refractory Multiple Myeloma Previously Treated With
  Daratumumab\, Lenalidomide and Bortezomib\nEstimated primary completion: 
 1 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ixa
 zomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04790474
URL:https://assetmemo.bio/drug/ixazomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07881809-2848@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20271008
DTEND;VALUE=DATE:20271009
SUMMARY:Ixazomib: Phase 2 readout est. (NCT07881809)
DESCRIPTION:Ixazomib\, phase 2.\nStudy: A Clinical Study of Ixazomib to Rea
 ctivate HIV and Reduce HIV Reservoir Size\nEstimated primary completion: 8
  October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ixazom
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7881809
URL:https://assetmemo.bio/drug/ixazomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03763162-2848@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Ixazomib: Phase 2 readout est. (NCT03763162)
DESCRIPTION:Ixazomib\, phase 2\, Multiple Myeloma.\nStudy: Daratumumab\, Bo
 rtezomib\, and Dexamethasone Followed by Daratumumab\, Ixazomib\, and Dexa
 methasone in Treating Patients With Relapsed or Refractory Multiple Myelom
 a\nEstimated primary completion: 30 October 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/ixazomib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03763162
URL:https://assetmemo.bio/drug/ixazomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03376672-2848@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ixazomib: Phase 2 readout est. (NCT03376672)
DESCRIPTION:Ixazomib\, phase 2\, Multiple Myeloma.\nStudy: Ixazomib Plus Le
 nalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients\nEstima
 ted primary completion: 31 December 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ixazomib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT03376672
URL:https://assetmemo.bio/drug/ixazomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06744894-2848@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Ixazomib: Phase 2 readout est. (NCT06744894)
DESCRIPTION:Ixazomib\, phase 2\, Multiple Myeloma.\nStudy: SIL as Maintenan
 ce Therapy in Multiple Myeloma\nEstimated primary completion: 1 January 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/ixazomib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06744894
URL:https://assetmemo.bio/drug/ixazomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04847453-2848@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Ixazomib: Phase 1 readout est. (NCT04847453)
DESCRIPTION:Ixazomib\, phase 1.\nStudy: Venetoclax\, MLN9708 (Ixazomib Citr
 ate) and Dexamethasone for the Treatment of Relapsed or Refractory Light C
 hain Amyloidosis\nEstimated primary completion: 30 June 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/ixazomib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04847453
URL:https://assetmemo.bio/drug/ixazomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04305691-2848@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20290315
DTEND;VALUE=DATE:20290316
SUMMARY:Ixazomib: Phase 2 readout est. (NCT04305691)
DESCRIPTION:Ixazomib\, phase 2.\nStudy: Trial of Ixazomib for Kaposi Sarcom
 a\nEstimated primary completion: 15 March 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ixazomib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT04305691
URL:https://assetmemo.bio/drug/ixazomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04998786-2848@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Ixazomib: Phase 2 readout est. (NCT04998786)
DESCRIPTION:Ixazomib\, phase 2\, Multiple Myeloma.\nStudy: A Multi-center O
 pen-label Phase 2 Study of Ixazomib\, Iberdomide and Dexamethasone in Elde
 rly Patients With Multiple Myeloma at First Relapse."\nEstimated primary c
 ompletion: 1 January 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ixazomib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04998786
URL:https://assetmemo.bio/drug/ixazomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
